Lazard Ltd
Change company Symbol lookup
Select an option...
LAZ Lazard Ltd
GRNH Greengro Technologies Inc
CLX Clorox Co
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
Go

Financials : Capital Markets | Small Cap Value
Based in Bermuda
Company profile

Lazard Ltd (Lazard) is a financial advisory and asset management company. The Company operates through two segments: Financial Advisory and Asset Management. It serves a range of clients around the world, including corporations, governments, institutions, partnerships and individuals. The Financial Advisory business segment offers corporate, partnership, institutional, government, sovereign and individual clients across the globe a range of financial advisory services regarding mergers and acquisitions (M&A) and other strategic matters, restructurings, capital structure, capital raising and various other financial matters to corporate, partnership, institutional, government, sovereign and individual clients. The Asset Management business provides investment solutions and investment management services in equity and fixed income strategies, alternative investments and private equity funds to corporations, public funds and sovereign entities.

Closing Price
$45.61
Day's Change
-1.20 (-2.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
46.44
Day's Low
45.38
Volume
(Heavy Day)
Volume:
900,055

10-day average volume:
653,779
900,055

Lawsuits Filed Against BMRN, BIIB and YY - Jakubowitz Law Pursues Shareholders Claims

10:15 am ET November 24, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

CONTACT JAKUBOWITZ ABOUT BMRN:https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=11170&from=1

Class Period : February 28, 2020 - August 18, 2020

Lead Plaintiff Deadline : November 24, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Biogen Inc. (NASDAQ:BIIB)

CONTACT JAKUBOWITZ ABOUT BIIB:https://claimyourloss.com/securities/biogen-inc-loss-submission-form/?id=11170&from=1

Class Period : October 22, 2019 - November 6, 2019

Lead Plaintiff Deadline : January 12, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Joyy Inc. (NASDAQ:YY)

CONTACT JAKUBOWITZ ABOUT YY:https://claimyourloss.com/securities/joyy-inc-loss-submission-form/?id=11170&from=1

Class Period : April 28, 2016 - November 18, 2020

Lead Plaintiff Deadline : January 19, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) The majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that Manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company's acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, Defendants' public statements were materially false and/or Misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com: https://www.accesswire.com/618205/Lawsuits-Filed-Against-BMRN-BIIB-and-YY--Jakubowitz-Law-Pursues-Shareholders-Claims

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.